

FIG. 1A




FIG. 1B





FIG. 1C

CTR - ARAS
MAY 30 2006
PATENT & TRADEMARK OFFICE



hSECURIN	FACS ANALYSIS (%)				CYTOLOGY (%)	
	G1	S	G2/M	APOPTOSIS	MITOSIS	INTERPHASE
+/+	69	17	14	2	1	97
-/-	70	16	14	1.8	0.7	97.5

FIG. 1F



FIG. 2A




FIG. 2B




FIG. 2C



FIG. 2D





FIG. 2E

BEST AVAILABLE COPY







FIG. 2G




FIG. 3A




FIG. 3B

BEST AVAILABLE COPY



-/-
hSECURIN (KO1)




FIG. 3C




FIG. 3D

OCT
MAY 30 2006
PATENT & TRADEMARK OFFICE




FIG. 4A




FIG. 4B

MITOTIC INTERVAL (MINUTES)	<i>hSECURIN</i>	
	<i>+/+</i>	<i>-/-</i>
PROPHASE TO METAPHASE	15	19
METAPHASE TO ANAPHASE	21	57
ANAPHASE TO TELOPHASE	17	16


FIG. 4C

BEST AVAILABLE COPY

© I.P.E. /ARAS
MAY 30 2006
PATENT & TRADEMARK OFFICE

HeLa
NOC RELEASE

0 1.5 2.5



HCT116
LOG PHASE
+/+ -/-




FIG. 5A




FIG. 5B




FIG. 5C

BEST AVAILABLE COPY




FIG. 6A




FIG. 6D

REST AVAILABLE COPY




FIG. 6B




FIG. 6C

RE~~F~~ST AVAILABLE COPY




FIG. 7